Literature DB >> 31342363

Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers.

Anita Mamtani1, Emily C Zabor2, Michelle Stempel1, Monica Morrow3.   

Abstract

BACKGROUND: The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial demonstrated that axillary lymph node dissection (ALND) may be omitted for women with two or fewer positive sentinel nodes (SLNs) undergoing breast-conservation therapy (BCT). Lobular histology comprises a minority of patients, and applicability to these discohesive cancers has been questioned.
METHODS: From August 2010 to March 2017, patients undergoing BCT for cT1-2N0 cancer with positive SLNs were prospectively managed with ALND for three or more positive SLNs or gross extracapsular extension (ECE). In this study, clinicopathologic characteristics and nodal burden were compared between pure/mixed invasive lobular cancer (ILC) and invasive ductal cancer (IDC) patients.
RESULTS: Among 813 consecutive patients, 104 (12.8%) had ILC and 709 (87.2%) had IDC. ILC was more often multifocal and low grade, and less frequently had lymphovascular invasion (all p < 0.001). ILC more often had SLN macrometastases (81.7% ILC vs. 69.4% IDC; p = 0.01) and more than 2 mm of ECE (30.8% ILC vs. 19.5% IDC; p = 0.03), but the proportions of cases with three or more positive SLNs were similar in the two groups (14.4% ILC vs. 9.9% IDC; p = 0.2). The ALND procedure was performed for 20 ILC patients (19.2%) compared with 97 IDC patients (13.7%) (p = 0.2). Additional positive nodes were found in 80% of the ILC patients versus 56.7% of the IDC patients (p = 0.09). The ALND and nodal burden rates were similar in the estrogen receptor-positive (ER+) subset analysis. In the multivariable analysis, lobular histology (p = 0.03) and larger tumors (p = 0.03) were associated with additional positive nodes. During a median follow-up period of 42 months, there were no isolated axillary recurrences.
CONCLUSIONS: Despite a higher proportion of SLN macrometastases and association with more positive nodes at ALND, lobular histology does not predict the need for ALND. ALND is not indicated on the basis of histology among patients otherwise meeting Z0011 criteria.

Entities:  

Mesh:

Year:  2019        PMID: 31342363      PMCID: PMC6669889          DOI: 10.1245/s10434-019-07536-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  21 in total

1.  Predicting the extent of nodal disease in early-stage breast cancer.

Authors:  Abigail S Caudle; Henry M Kuerer; Huong T Le-Petross; Wei Yang; Min Yi; Isabelle Bedrosian; Savitri Krishnamurthy; Bruno D Fornage; Kelly K Hunt; Elizabeth A Mittendorf
Journal:  Ann Surg Oncol       Date:  2014-05-24       Impact factor: 5.344

2.  Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement.

Authors:  Stacy Ugras; Michelle Stempel; Sujata Patil; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2014-06-21       Impact factor: 5.344

3.  Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.

Authors:  Ingrid G M Poodt; Pauline E R Spronk; Guusje Vugts; Thijs van Dalen; M T F D Vrancken Peeters; Marjolijn L Rots; Anne Kuijer; Grard A P Nieuwenhuijzen; Robert-Jan Schipper
Journal:  Ann Surg       Date:  2018-12       Impact factor: 12.969

4.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.

Authors:  Robert E Mansel; Lesley Fallowfield; Mark Kissin; Amit Goyal; Robert G Newcombe; J Michael Dixon; Constantinos Yiangou; Kieran Horgan; Nigel Bundred; Ian Monypenny; David England; Mark Sibbering; Tholkifl I Abdullah; Lester Barr; Utheshtra Chetty; Dudley H Sinnett; Anne Fleissig; Dayalan Clarke; Peter J Ell
Journal:  J Natl Cancer Inst       Date:  2006-05-03       Impact factor: 13.506

Review 5.  Lobular breast carcinoma and its variants.

Authors:  Emad A Rakha; Ian O Ellis
Journal:  Semin Diagn Pathol       Date:  2010-02       Impact factor: 3.464

6.  Presenting features of breast cancer differ by molecular subtype.

Authors:  Lisa Wiechmann; Michelle Sampson; Michelle Stempel; Lindsay M Jacks; Sujata M Patil; Tari King; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2009-07-11       Impact factor: 5.344

7.  Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients.

Authors:  Elizabeth A Mittendorf; Aysegul A Sahin; Susan L Tucker; Funda Meric-Bernstam; Min Yi; Khazi M Nayeemuddin; Gildy V Babiera; Merrick I Ross; Barry W Feig; Henry M Kuerer; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2008-09-25       Impact factor: 5.344

8.  A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy.

Authors:  Kimberly J Van Zee; Donna-Marie E Manasseh; Jose L B Bevilacqua; Susan K Boolbol; Jane V Fey; Lee K Tan; Patrick I Borgen; Hiram S Cody; Michael W Kattan
Journal:  Ann Surg Oncol       Date:  2003-12       Impact factor: 5.344

9.  Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up.

Authors:  Lee K Tan; Dilip Giri; Amanda J Hummer; Katherine S Panageas; Edi Brogi; Larry Norton; Clifford Hudis; Patrick I Borgen; Hiram S Cody
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

10.  Predicting likelihood of having four or more positive nodes in patient with sentinel lymph node-positive breast cancer: a nomogram validation study.

Authors:  Bulent Unal; Akif Serhat Gur; Sushil Beriwal; Gong Tang; Ronald Johnson; Gretchen Ahrendt; Marguerite Bonaventura; Atilla Soran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-26       Impact factor: 7.038

View more
  2 in total

1.  ASO Author Reflections: Early-Stage Lobular Breast Cancer: Axillary Treatment in the Z0011 Era.

Authors:  Anita Mamtani; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2019-08-29       Impact factor: 5.344

2.  Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater.

Authors:  Mary Kathryn Abel; Case E Brabham; Ruby Guo; Kelly Fahrner-Scott; Jasmine Wong; Michael Alvarado; Cheryl Ewing; Laura J Esserman; Rita A Mukhtar
Journal:  Am J Surg       Date:  2020-06-19       Impact factor: 2.565

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.